{"name":"Shanghai Miracogen Inc.","slug":"shanghai-miracogen-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"Cetuximab injection","genericName":"Cetuximab injection","slug":"cetuximab-injection","indication":"Metastatic colorectal cancer (KRAS wild-type)","status":"phase_3"},{"name":"Gemcitabine, Docetaxel, or Capecitabine","genericName":"Gemcitabine, Docetaxel, or Capecitabine","slug":"gemcitabine-docetaxel-or-capecitabine","indication":"Advanced or metastatic solid tumors (specific indication under investigation in phase 3 trial)","status":"phase_3"},{"name":"MRG002","genericName":"MRG002","slug":"mrg002","indication":"Solid tumors (specific indication under investigation in phase 3)","status":"phase_3"},{"name":"Trastuzumab Emtansine for Injection","genericName":"Trastuzumab Emtansine for Injection","slug":"trastuzumab-emtansine-for-injection","indication":"Adjuvant treatment of HER2-positive breast cancer","status":"phase_3"},{"name":"MRG003","genericName":"MRG003","slug":"mrg003","indication":"Solid tumors (specific indications in phase 3 trials not fully disclosed in public domain)","status":"phase_3"},{"name":"MRG003 + Pucotenlimab","genericName":"MRG003 + Pucotenlimab","slug":"mrg003-pucotenlimab","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"MRG004A plus best supportive care","genericName":"MRG004A plus best supportive care","slug":"mrg004a-plus-best-supportive-care","indication":"Advanced or metastatic solid tumors (Phase 3 indication under investigation)","status":"phase_3"},{"name":"Pemetrexed Disodium Injection","genericName":"Pemetrexed Disodium Injection","slug":"pemetrexed-disodium-injection","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"MRG004A","genericName":"MRG004A","slug":"mrg004a","indication":"Other","status":"phase_1"},{"name":"Placebo plus best supportive care","genericName":"Placebo plus best supportive care","slug":"placebo-plus-best-supportive-care","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Cetuximab injection","genericName":"Cetuximab injection","slug":"cetuximab-injection","phase":"phase_3","mechanism":"Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing growth signals and inducing cell death.","indications":["Metastatic colorectal cancer (KRAS wild-type)","Head and neck squamous cell carcinoma","Non-small cell lung cancer"],"catalyst":""},{"name":"Gemcitabine, Docetaxel, or Capecitabine","genericName":"Gemcitabine, Docetaxel, or Capecitabine","slug":"gemcitabine-docetaxel-or-capecitabine","phase":"phase_3","mechanism":"This is a combination of three chemotherapy agents that work through different mechanisms to inhibit cancer cell growth and division.","indications":["Advanced or metastatic solid tumors (specific indication under investigation in phase 3 trial)"],"catalyst":""},{"name":"MRG002","genericName":"MRG002","slug":"mrg002","phase":"phase_3","mechanism":"MRG002 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity.","indications":["Solid tumors (specific indication under investigation in phase 3)"],"catalyst":""},{"name":"Trastuzumab Emtansine for Injection","genericName":"Trastuzumab Emtansine for Injection","slug":"trastuzumab-emtansine-for-injection","phase":"phase_3","mechanism":"Trastuzumab emtansine targets the HER2 protein on cancer cells and delivers a toxic payload to kill them.","indications":["Adjuvant treatment of HER2-positive breast cancer","Treatment of HER2-positive breast cancer","Treatment of HER2-positive gastric cancer"],"catalyst":""},{"name":"MRG003","genericName":"MRG003","slug":"mrg003","phase":"phase_3","mechanism":"MRG003 is a bispecific antibody that simultaneously engages tumor cells and immune cells to enhance anti-tumor immunity.","indications":["Solid tumors (specific indications in phase 3 trials not fully disclosed in public domain)"],"catalyst":""},{"name":"MRG003 + Pucotenlimab","genericName":"MRG003 + Pucotenlimab","slug":"mrg003-pucotenlimab","phase":"phase_3","mechanism":"MRG003 is a bispecific antibody targeting PD-L1 and 4-1BB that enhances T-cell activation, while Pucotenlimab is a PD-L1 inhibitor, together blocking immune checkpoints to reinvigorate anti-tumor immunity.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"MRG004A","genericName":"MRG004A","slug":"mrg004a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MRG004A plus best supportive care","genericName":"MRG004A plus best supportive care","slug":"mrg004a-plus-best-supportive-care","phase":"phase_3","mechanism":"MRG004A is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 indication under investigation)"],"catalyst":""},{"name":"Pemetrexed Disodium Injection","genericName":"Pemetrexed Disodium Injection","slug":"pemetrexed-disodium-injection","phase":"phase_3","mechanism":"Pemetrexed is a folate antagonist that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells.","indications":["Non-small cell lung cancer (NSCLC)","Mesothelioma","Colorectal cancer"],"catalyst":""},{"name":"Placebo plus best supportive care","genericName":"Placebo plus best supportive care","slug":"placebo-plus-best-supportive-care","phase":"phase_3","mechanism":"Placebo plus best supportive care provides no active pharmacological intervention, serving as a control arm to evaluate the efficacy of investigational treatments.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNc1lsTmVGYmFzSGkzRXlVX2RMeDI2UlQ0VVJBVkhYMkQ1VlpaMFNCX3gtdzBwZEU5UWtUbWNPWmxhMm5jQ3AyMWtMMXhkVW9RSlM2bTNzVy1SdUt6Vmp0Wjk3T0tvUGZHQktEc1B0aTBBbUNfelU4XzFoOHZWVEdrVFpNYklZbFZNQWFDUlFhbVFaaDdYVE03VlNvdk9VczhYY2Q2Ul9KX0F3c3RKQk1QZVQxa3BuOEJOMnQ2Q1lwc3hLYkc5UEtSWm1wTVNHMVpaQ2Y1SmQ3dGljYS1aWjNIWVotRUI1T1lTLUZMb3ROenV5T2ZPOVl5cnVBV19CbTNabnRhOGQzSXhhY1pDWnBXOGFabw?oc=5","date":"2026-03-21","type":"trial","source":"Barchart.com","summary":"HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Ma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNR29wLTRZb0FBMGRqRDV0d25jRWJDb3NlaFg5Qkc0NkRRUnFsZG1CNzdJaEZzV1JjLWxtYnVrVElHX0NfX1JyVHlFRXlHWUdWdHdLLW9qbFBIYTdEckU0SXB0b0ZYRUNZX1JWT0kzczBZN3VPakxnX1h3WlpBcGJkTDdVRlMyeGhiRDBYblllVHJaZw?oc=5","date":"2026-03-21","type":"trial","source":"openPR.com","summary":"HER2 Positive Gastric Cancer Clinical Trial Pipeline - openPR.com","headline":"HER2 Positive Gastric Cancer Clinical Trial Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNZGtWZHFNbTBHS1YyTU1ENWd4Y09VQ3ZPbWQ2NmZyUHlVbl8zdU5JR1hwbl9aN2xQdlNHaWNSdWV4cjlOdEhHMGVSeEtkaWlVOFN5dGRZZHRHLUN4b1dBUmFGNGVIcWhTTi1NTnNnb00yUDlkLXRzTWVtTFZyT1ozbUtGTmxlUnZzZmEwQkZXSEVIXzR1VkxDWlluLVRXR0tDdTZteTQ0V2ZFbGM3TmJjVWM1TEI4MUlHWnRCOEwydmx6YUtreVMybWJoUWxkSkZtb3dYb1VJNjVLSTdFNWotdGY1ZnlxdnNRWkt1Q2VCeGVvbVpfUWptOXlISkhNZ01FQWF3Zks5YWVJQ0FVYkVpV2x1TnVTdVpK?oc=5","date":"2025-06-09","type":"regulatory","source":"PR Newswire","summary":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPUHpZTk5mTk42aDAyUG0xVTZyOWQ0MEFmdlVaRHdFSHFJMW9tWFFKQjBHT0FjTmppOWpnNDhuWE1ucDlMQUpsVEdjaTRud3Q5YjhtT191SzA0cVAtbndVMXREcVYxMlU2TjhkWk5fRW5ieWlJM1htbW9SbjJOODhiVUl6VDhLZGhVS0psbGNkMXhISXBlNE40WFRoTkZtWTFvVExBc1pzNFN2SFNfVHNFNlVmdWZfOWtmNkFidDRuOWh1NEUtZUw2aEh2TmZCcjdKQ3F1TXJUNFVGYTBKTVJaVFQ2d3A1SWhzc1dVMnU1Snl0U0Q2dVBn?oc=5","date":"2025-03-04","type":"pipeline","source":"GlobeNewswire","summary":"BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight - GlobeNewswire","headline":"BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOcUlQTUJfYUhhNk9VZXNXQ3JWYlExd0hqYzkyOW5HV2htMmlzQXE1akZKbFJFTzNHTmo4VWVjdFctUjZfRW1mOGVPcmdIcDdJTzhZSW5YWTB5VURpWlFPTG9Sd05OS0pnTWpkc3RQdDdmSXo0T2F5eVhINHc4MF8tUTVyXzBMTHpRZEk1blZ0SkV1YWFXaE1TRVEwRVJ6Q3B3MlJoTC1fWnJmQ21SQ0MydFIwMjNlMWpXS08tZ01paU9Da2QyRUtCdU94cWFEQ1N6enNURGQ3WGstNWxieVVlblNteHM2OVd0M3c?oc=5","date":"2025-02-04","type":"pipeline","source":"PR Newswire","summary":"Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29% by 2032 | DelveInsight - PR Newswire","headline":"Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29% by 2032 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNZEZWS2U4SUdrSUIzZ3FCUjV0NWFOM3o5T1NsOVR0RVFGeUlQOEtESnVHTkV6R0lXU18xanE1WUNDYlhFb1VqY09CMXh5NnJfX2p2cER3cWFuSUJQVm12SVRsaThOdnBxamtUZ1ZGamNZM3U5bkw1M2h6eFB6YmZLdFphSlU0SUtwaHJpSk9aUzU4enVTM1c5SEo3ODRZSlFkM0daX1ctUTRQWXpENXpQaTBn?oc=5","date":"2025-01-23","type":"deal","source":"BioWorld News","summary":"More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal - BioWorld News","headline":"More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOM21NWGJUU3VHRnF1NzFjNk1RelV4RGVxWXVYN19jNGhVNjZIekt5YktjYTRBejRQeGE2VWd6V0RESG92eldPZms4RDlFZ0kxWmdtb0Z2ODFtR1ZTQWJCM0Nha0p4YXhoazJrdV9rYzVUVDlxTnAyVXRMOTdkeTR1S3ZyMDJ3TW4xU3lQa0pNY1dzeGt1R0E4Xy14bFlISWJkck1WRUdDMTFzOW5YOWlHalB5ZmpZcWR2dGxNNTEzbGhyUklaZWtWMG9fTWU1NGtPRWRIS3AyanphRFhaYmQtTGRIX21YNkRKYS1aUDNRbFFjWnN3Ti1GX3JOc3Y?oc=5","date":"2024-10-17","type":"pipeline","source":"PR Newswire","summary":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight - PR Newswire","headline":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNbDVNY2Vtekhac0k0RU5Rc0hGN3FTVFA2UTRaMlRvbnduYW54TEtEUFpmdjIzYWUxQ1k1Rmt4R3JtVEtPTkFQMWRhTmxtOEctdGJMN0RCSlJ2dWxsWWRkN0xucC1ETkxZSnhEX0JEeGZVTXpTMjZSeDJwbWphbGRQa3lNTEFkTG5XOUZDZ1ZSa0JXWFlUbGFhRDZ0M29QSlIxQUg1Rk8wMXlUUEFEWG5CQndyS0tDQVp2T2tmM0lzeTZRSEtIbk1DVzY3ZWVpX0RZcWJ6MWtSS0FJd21JTTNwVXcxeHpBSXJlVHl3MmIxMUtlQWVLaVlfTVhvWUdobkRiVDFTM0pkWTFYSHo4RjN3TU1VYUV5dk1XZjRya3ptcUwwREpUamVveE9QYU4zSUxSU3djOWZNTQ?oc=5","date":"2024-10-01","type":"trial","source":"GlobeNewswire","summary":"Breast Cancer Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Breast Cancer Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-07-12","type":"pipeline","source":"GlobeNewswire","summary":"Antibody Drug Conjugates Market Insights 2018-2023 and - GlobeNewswire","headline":"Antibody Drug Conjugates Market Insights 2018-2023 and","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_3":9,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}